Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer have been revised. It is anticipated that the appraisal will begin in early-January 2024 when we will write to you about how you can get involved.